Bayer Should Stress Clot Risk On Yaz Label: FDA Panel

Law360, New York (December 8, 2011, 10:15 PM EST) -- A U.S. Food and Drug Administration panel reportedly recommended Thursday that Bayer AG revise the labels on its Yaz and Yasmin contraceptives to highlight increased blood clot risks associated with the drugs, but said the pills are a beneficial choice for contraception.

In a panel meeting held Thursday in Adelphi, Md., a majority of the 26 panelists voted that the drugs’ labels did not contain enough warning to stress their increased risks of serious side effects including deep vein thrombosis, or the formation of a clot...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.